[go: up one dir, main page]

AR061627A1 - Formas de dosificacion solidas de valsartan, amlodipina, e hidroclorotiazida, y metodo para elaborarlas - Google Patents

Formas de dosificacion solidas de valsartan, amlodipina, e hidroclorotiazida, y metodo para elaborarlas

Info

Publication number
AR061627A1
AR061627A1 ARP070102798A ARP070102798A AR061627A1 AR 061627 A1 AR061627 A1 AR 061627A1 AR P070102798 A ARP070102798 A AR P070102798A AR P070102798 A ARP070102798 A AR P070102798A AR 061627 A1 AR061627 A1 AR 061627A1
Authority
AR
Argentina
Prior art keywords
solid dosage
valsartan
mixed
dosage forms
hydroclorotiazida
Prior art date
Application number
ARP070102798A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38662673&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR061627(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR061627A1 publication Critical patent/AR061627A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Reivindicacion 1: Una forma de dosificacion solida, la cual comprende: valsartan; amlodipina; hidroclorotiazida; y aditivos farmacéuticamente aceptables adecuados para la preparacion de las formas de dosificacion solidas de valsartan. Reivindicacion 14: Un método para la elaboracion de una forma de dosificacion solida, el cual comprende los pasos de: (a) mezclar valsartan, amlodipina, hidroclorotiazida, y aditivos farmacéuticamente aceptables, para formar un material mezclado; (b) tamizar el material mezclado para formar un material tamizado; (c) mezclar el material tamizado para formar un material mezclado/tamizado; (d) compactar el material mezclado/tamizado para formar un material compactado; (e) moler el material compactado para formar un material molido; (f) mezclar el material molido para formar un material mezclado/molido; y (g) comprimir el material mezclado/molido para formar una forma de dosificacion solida en una sola capa.
ARP070102798A 2006-06-27 2007-06-25 Formas de dosificacion solidas de valsartan, amlodipina, e hidroclorotiazida, y metodo para elaborarlas AR061627A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80588306P 2006-06-27 2006-06-27

Publications (1)

Publication Number Publication Date
AR061627A1 true AR061627A1 (es) 2008-09-10

Family

ID=38662673

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102798A AR061627A1 (es) 2006-06-27 2007-06-25 Formas de dosificacion solidas de valsartan, amlodipina, e hidroclorotiazida, y metodo para elaborarlas

Country Status (22)

Country Link
US (2) US20100003321A1 (es)
EP (1) EP2037893A2 (es)
JP (1) JP2009542709A (es)
KR (1) KR20090021191A (es)
CN (2) CN101478956B (es)
AR (1) AR061627A1 (es)
AU (1) AU2007265138A1 (es)
BR (1) BRPI0713785A2 (es)
CA (1) CA2654986A1 (es)
CL (1) CL2007001870A1 (es)
EC (1) ECSP088987A (es)
IL (1) IL195797A0 (es)
MA (1) MA30529B1 (es)
MX (1) MX2008016532A (es)
NO (1) NO20090314L (es)
NZ (1) NZ573295A (es)
PE (2) PE20080991A1 (es)
RU (1) RU2449786C2 (es)
TN (1) TNSN08538A1 (es)
TW (1) TW200808379A (es)
WO (1) WO2008002905A2 (es)
ZA (1) ZA200810053B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3239B1 (ar) * 2008-09-22 2018-03-08 Novartis Ag تركيبات جالينية من مركبات عضوية
CN102316875A (zh) 2009-02-13 2012-01-11 贝林格尔.英格海姆国际有限公司 用于治疗i型糖尿病、ii型糖尿病、葡萄糖耐量降低或高血糖症的sglt-2抑制剂
US20120107397A1 (en) * 2009-07-03 2012-05-03 Hetero Research Foundation Pharmaceutical compositions of valsartan
ES2546762T3 (es) 2009-09-30 2015-09-28 Boehringer Ingelheim International Gmbh Procedimientos para preparar derivados de bencil-benceno sustituidos con glucopiranosilo
UY32919A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
CN102091069A (zh) * 2009-12-11 2011-06-15 浙江华海药业股份有限公司 缬沙坦和氨氯地平的复方制剂及其制备方法
CN101897675B (zh) * 2010-02-10 2012-11-21 温士顿医药股份有限公司 含有凡尔沙坦或其药学上可接受的盐的固体剂型口服医药组成物
CN101829111B (zh) * 2010-05-23 2014-12-17 浙江华海药业股份有限公司 含有缬沙坦的固体制剂及其制备方法
CN102716132B (zh) * 2011-03-29 2015-09-30 石药集团中奇制药技术（石家庄）有限公司 复方氨氯地平/缬沙坦/氢氯噻嗪片及其制备方法
AU2012360935A1 (en) * 2011-12-26 2014-07-17 Novartis Ag Tablets and dry-coated agents
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN102614190A (zh) * 2012-04-17 2012-08-01 北京哈三联科技股份有限公司 含有缬沙坦、氨氯地平和氢氯噻嗪的片剂及其制备方法
JP6018420B2 (ja) * 2012-06-05 2016-11-02 ニプロ株式会社 アンジオテンシンｉｉ受容体拮抗薬およびサイアザイド系利尿薬を含む医薬組成物
MX358211B (es) 2012-07-23 2018-08-10 Landsteiner Scient S A De C V Una composición farmacéutica de liberación comprendiendo hidroclorotiazida, losartán y basilato de amlodipino.
CN103655580B (zh) * 2012-08-28 2017-12-01 海南中济医药科技有限公司 一种含有缬沙坦、苯磺酸氨氯地平和氢氯噻嗪的药物组合物及其制备方法
TW201427720A (zh) * 2012-10-12 2014-07-16 Ajinomoto Kk 含有鈣拮抗劑及血管張力素ｉｉ受體拮抗劑之醫藥製劑之製造方法
CN102846625A (zh) * 2012-10-18 2013-01-02 海口华仕联医药科技有限公司 一种稳定的缬沙坦、氨氯地平和氢氯噻嗪的药物组合及其制备方法
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
ES2702174T3 (es) 2013-04-05 2019-02-27 Boehringer Ingelheim Int Usos terapéuticos de empagliflozina
HK1213818A1 (zh) 2013-04-05 2016-07-15 勃林格殷格翰国际有限公司 依帕列净的治疗用途
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
DK2986304T3 (da) 2013-04-18 2022-04-04 Boehringer Ingelheim Int Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf.
CZ2013783A3 (cs) 2013-10-08 2015-04-15 Zentiva, K. S Stabilní farmaceutická kompozice obsahující amlodipin a valsartan
CN105106962A (zh) * 2015-08-29 2015-12-02 西安力邦肇新生物科技有限公司 一种复方降压制剂及其应用
EP3463309B1 (en) * 2016-05-30 2020-06-17 Boehringer Ingelheim International GmbH Fixed dose combination of telmisartan, hydrochlorothiazide and amlodipine
CN109922813A (zh) 2016-11-10 2019-06-21 勃林格殷格翰国际有限公司 药物组合物、治疗方法及其用途
MY199557A (en) 2017-02-27 2023-11-07 Idorsia Pharmaceuticals Ltd Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases
WO2019008485A1 (en) 2017-07-06 2019-01-10 Mankind Pharma Ltd FIXED DOSE PHARMACEUTICAL COMPOSITION BASED ON VALSARTAN AND SACUBITRIL
IL274943B2 (en) 2017-11-30 2025-04-01 Idorsia Pharmaceuticals Ltd Combination of a 4-pyrimidinsulfamide derivative with an SGLT-2 inhibitor for the treatment of endothelin-related diseases
WO2022132067A1 (en) * 2020-12-18 2022-06-23 Santa Farma Ilac Sanayii A.S. Stable bilayer tablet compositions
CN113171352A (zh) * 2021-04-15 2021-07-27 海南锦瑞制药有限公司 一种沙坦类降压复方制剂的制备方法
GR1010320B (el) * 2021-08-04 2022-10-11 Win Medica Φαρμακευτικη Ανωνυμη Εταιρεια, Στερεες φαρμακοτεχνικες μορφες ιρβεσαρτανης, υδροχλωροθειαζιδης και αμλοδιπινης

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057344A (en) * 1991-11-26 2000-05-02 Sepracor, Inc. Methods for treating hypertension, and angina using optically pure (-) amlodipine
EP0795327A1 (en) * 1996-03-13 1997-09-17 Pfizer Inc. Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin
RU2188636C2 (ru) * 1998-03-26 2002-09-10 Др. Редди'С Лабораторис Лтд. Стабильный фармацевтический препарат, содержащий амлодипина безилат и атенолол
AU2002226365A1 (en) * 2000-12-01 2002-06-11 Novartis Ag Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
ES2298351T5 (es) * 2002-01-16 2012-01-26 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Método para producir un comprimido farmacéutico de dos capas que comprenden telmisartán e hidroclorotiazida.
US6869970B2 (en) 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
AUPS236902A0 (en) * 2002-05-16 2002-06-13 Northern Sydney Area Health Service Composition and method for treating hypertension
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
KR100580168B1 (ko) 2003-03-21 2006-05-16 삼성전자주식회사 다중 홈 에이전트 제어장치 및 방법
WO2005070462A2 (en) 2004-01-12 2005-08-04 Sepracor, Inc. Compositions comprising (s)-amlodipine and an angiotensin receptor blocker and methods of their use
AU2005245026B2 (en) 2004-05-21 2010-07-01 Accu-Break Technologies, Inc. Immediate release pharmaceutical tablets with height greater than width
EA013053B1 (ru) * 2004-11-05 2010-02-26 Бёрингер Ингельхайм Интернациональ Гмбх Двуслойная таблетка, содержащая телмисартан и амлодипин
CN100389830C (zh) * 2005-05-08 2008-05-28 广州市施柏医药科技有限公司 一种治疗高血压的药物组合物

Also Published As

Publication number Publication date
EP2037893A2 (en) 2009-03-25
KR20090021191A (ko) 2009-02-27
NO20090314L (no) 2009-01-26
CN101478956B (zh) 2013-03-20
MX2008016532A (es) 2009-01-19
HK1133818A1 (en) 2010-04-09
RU2449786C2 (ru) 2012-05-10
US20120164218A1 (en) 2012-06-28
ECSP088987A (es) 2009-01-30
PE20080991A1 (es) 2008-09-05
IL195797A0 (en) 2009-09-01
JP2009542709A (ja) 2009-12-03
NZ573295A (en) 2012-01-12
US20100003321A1 (en) 2010-01-07
ZA200810053B (en) 2009-11-25
CA2654986A1 (en) 2008-01-03
TW200808379A (en) 2008-02-16
WO2008002905A3 (en) 2008-12-11
PE20120542A1 (es) 2012-05-14
US8475839B2 (en) 2013-07-02
TNSN08538A1 (en) 2010-04-14
RU2009102273A (ru) 2010-08-10
CL2007001870A1 (es) 2008-06-13
MA30529B1 (fr) 2009-06-01
CN101478956A (zh) 2009-07-08
AU2007265138A1 (en) 2008-01-03
WO2008002905A2 (en) 2008-01-03
BRPI0713785A2 (pt) 2012-10-30
CN103169711A (zh) 2013-06-26

Similar Documents

Publication Publication Date Title
AR061627A1 (es) Formas de dosificacion solidas de valsartan, amlodipina, e hidroclorotiazida, y metodo para elaborarlas
PE20060195A1 (es) Proceso para la preparacion de una forma de dosificacion solida a prueba de abuso
AR055120A1 (es) Formas de dosis solidas de valsartan y amlodipina y metodo para hacer las mismas
CY1110241T1 (el) Φαρμακευτικο σκευασμα που περιλαμβανει ενωσεις λανθανιου
CL2017001540A1 (es) Composición para prevenir enfermedades en plantas y un método para prevenirlas.
MX272145B (es) Materiales compuestos de nanofibras y metodos para hacer los mismos.
MX2013003900A (es) Materiales compuestos que incluyen nanoparticulas, herramientas para perforacion en la tierra y componentes que incluyen tales materiales compuestos, materiales policristalinos que incluyen nanoparticulas y metodos relacionados.
IL177087A0 (en) Controlled-release pharmaceutical composition and method for producing the same
EA200500055A1 (ru) Способ обработки подземных пластов
NO20083720L (no) Fremgangsmater og sammensetninger for antagonisme av RAGE
EA200870573A1 (ru) Растворимые табачные пластинки и способ их изготовления
BRPI0818680A2 (pt) composição farmacêutica, preparação farmacêutica, e método para preparar um forma de dosagem oral farmacêutica
HN2006014095A (es) Forma cristalina ortorrombica del maleato de asenapina
BRPI0814471A2 (pt) Preparação de anticorpo, método para produzir a preparação de anticorpo, composição farmacêutica, kit de partes, e, uso de uma preparação de anticorpo
ITTO20040390A1 (it) Composizione, in particolare per uso farmaceutico, ad azione antiossidante, antinfiammatoria ed immunostimolante.
IL184314A0 (en) Substituted 4-phenyltetrahydroisoquinolines, methods for producing them, their use as drug, and drug containing them
EA200701886A1 (ru) Способ получения кальциевых композиций в непрерывном псевдоожиженном слое
CL2008001042A1 (es) Metodo para preparar compuestos derivados de imidazol; y un metodo para incrementar de mayor a menor la relacion de isomeros en una mezcla de dichos compuestos.
BRPI0817863A2 (pt) Camada de proteção mecânica para uma forma de dosagem, forma de dosagem sólida famaceuticamente aceitável, comprimido, uso de uma camada de proteção mecânica e métodos para a preparação de camada de proteção mecãnica
CL2012000109A1 (es) Forjado para plantas de construccion que determina una superficie de construccion mediante piezas modulares asociadas y que poseen un bloque prismatico rectangular, un canal longitudinal, ranuras profundas y poco profundas, una masa de pegamento de hormigon, una estructura de celosia, una conformacion entrante y una conformacion prominente.
ITTV20040103A1 (it) Procedimento per la fabbricazione di manufatti in lastre sottili di pietra composita e manufatti risultanti.
EP1566456A4 (en) COMPOSITE MATERIAL, MANUFACTURING METHOD DAF R AND ELEMENT THEREWITH
PL1951738T3 (pl) Nowe formy krystaliczne rostafuroksyny
ITMI20040443A1 (it) Prpcesso per la preparazione di ..15-16-17-cheto-steroidi e loro uso nella sintesi di composti farmacologicamente attivi
GB2435185B (en) Sparse table compaction method

Legal Events

Date Code Title Description
FA Abandonment or withdrawal